Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo

被引:58
作者
Mouton, JW
van Ogtrop, LL
Andes, D
Craig, WA
机构
[1] Canisius Wilhelmina Hosp, Dept Med Microbiol, NL-6532 SZ Nijmegen, Netherlands
[2] Erasmus Univ, Rotterdam, Netherlands
[3] Leiden Univ, Med Ctr, Leiden, Netherlands
[4] Univ Wisconsin, Madison, WI USA
关键词
D O I
10.1128/AAC.43.10.2473
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Although combination therapy with antimicrobial agents is often used, no available method explains or predicts the efficacies of these combinations satisfactorily. Since the efficacies of antimicrobial agents can be described by pharmacodynamic indices (PDIs), such as area under the concentration-time curve (AUC), peak level, and the time that the concentration is above the MIC (time > MIC), it was hypothesized that the same PDIs would be valid in explaining efficacy during combination therapy. Twenty-four-hour efficacy data (numbers of CFU) for Pseudomonas aeruginosa in a neutropenic mouse thigh model were determined for various combination regimens: ticarcillin-tobramycin (n = 41 different regimens), ceftazidime-netilmicin (n = 60), ciprofloxacin-ceftazidime (n = 59), netilmicin-ciprofloxacin (It = 38) and for each of these agents given singly. Multiple regression analysis was used to determine the importance of various PDIs (time > MIC, time > 0.25 x the MIG, time > 4x the MIC, peak level, AUG, AUC/MIC, and their logarithmically transformed values) during monotherapy and combination therapy, The PDIs that best explained the efficacies of single-agent regimens were time > 0.25x the MIC for beta-lactams and log AUC/MIC for ciprofloxacin and the aminoglycosides. For the combination regimens, regression analysis showed that efficacy could best be explained by the combination of the two PDIs that each best explained the response for the respective agents given singly. ri regression model for the efficacy of combination therapy was developed by use of a linear combination of the regression models of the PDI with the highest R-2 for each agent given singly. The model values for the single-agent therapies were then used in that equation, and the predicted values that were obtained were compared with the experimental values. The responses of the combination regimens could best be predicted by the sum of the responses of the single-agent regimens as functions of their respective PDIs (e.g., time>0.25 x the MIC for ticarcillin and log AUC/MIC for tobramycin), The relationship between the predicted response and the observed response for the combination regimens may be useful for determination of the presence of synergism, We conclude that the PDIs for the individual drugs used in this study are class dependent and predictive of outcome not only when the drugs are given as single agents but also when they are given in combination. When given in combination, there appears to be a degree of synergism independent of the dosing regimen applied.
引用
收藏
页码:2473 / 2478
页数:6
相关论文
共 28 条
[1]   ANTIBIOTIC SYNERGY IN EXPERIMENTAL INFECTION WITH PSEUDOMONAS .2. EFFECT OF CARBENICILLIN, CEPHALOTHIN, OR CEPHANONE COMBINED WITH TOBRAMYCIN OR GENTAMICIN [J].
ANDRIOLE, VT .
JOURNAL OF INFECTIOUS DISEASES, 1974, 129 (02) :124-133
[2]  
[Anonymous], MANUAL CLIN MICROBIO
[3]  
BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
[4]  
BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
[5]   CORRELATIONS BETWEEN METHODS FOR MEASUREMENT OF SYNERGY [J].
BERENBAUM, MC .
JOURNAL OF INFECTIOUS DISEASES, 1980, 142 (03) :476-478
[6]  
BLASER J, 1991, SCAND J INFECT DIS, P71
[7]   INVITRO ACTIVITY OF CIPROFLOXACIN IN COMBINATION WITH CEFTAZIDIME, AZTREONAM, AND AZLOCILLIN AGAINST MULTIRESISTANT ISOLATES OF PSEUDOMONAS-AERUGINOSA [J].
BUSTAMANTE, CI ;
WHARTON, RC ;
WADE, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1814-1815
[8]   ANTIMICROBIAL ACTIVITY OF CIPROFLOXACIN AGAINST PSEUDOMONAS-AERUGINOSA, ESCHERICHIA-COLI, AND STAPHYLOCOCCUS-AUREUS DETERMINED BY THE KILLING CURVE METHOD - ANTIBIOTIC COMPARISONS AND SYNERGISTIC INTERACTIONS [J].
CHALKLEY, LJ ;
KOORNHOF, HJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (02) :331-342
[9]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40
[10]   Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics [J].
den Hollander, JG ;
Mouton, JW ;
Verbrugh, HA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :744-748